AAD 2023: Upadacitinib Provides Early, Long-Lasting Relief for Atopic Dermatitis
Improvements seen for itch, sleep, and quality-of-life responses versus placebo in three randomized trials
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.